{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:21:10Z","timestamp":1771489270975,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jiph.2024.102583","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T05:00:29Z","timestamp":1730437229000},"page":"102583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4506-0843","authenticated-orcid":false,"given":"Wei","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3443-2522","authenticated-orcid":false,"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changsong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaijiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jiph.2024.102583_bib1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"issue":"1142","key":"10.1016\/j.jiph.2024.102583_bib2","first-page":"753","article-title":"Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19)","volume":"96","author":"Umakanthan","year":"2020","journal-title":"Post Med J"},{"issue":"4","key":"10.1016\/j.jiph.2024.102583_bib3","doi-asserted-by":"crossref","DOI":"10.1097\/CCE.0000000000000109","article-title":"The clinical presentation and immunology of viral pneumonia and implications for management of coronavirus disease 2019","volume":"2","author":"Darden","year":"2020","journal-title":"Crit Care Explor"},{"issue":"1","key":"10.1016\/j.jiph.2024.102583_bib4","first-page":"20","article-title":"COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management","volume":"29","author":"Ochani","year":"2021","journal-title":"Infez Med"},{"key":"10.1016\/j.jiph.2024.102583_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1053814","article-title":"How to use COVID-19 antiviral drugs in patients with chronic kidney disease","volume":"14","author":"Kale","year":"2023","journal-title":"Front Pharm"},{"issue":"11","key":"10.1016\/j.jiph.2024.102583_bib6","first-page":"970","article-title":"Potential therapeutic drugs for novel coronavirus pneumonia]","volume":"43","author":"Nie","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"1","key":"10.1016\/j.jiph.2024.102583_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41392-020-00351-z","article-title":"Azvudine (FNC): a promising clinical candidate for COVID-19 treatment","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jiph.2024.102583_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101981","article-title":"Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study","volume":"59","author":"Sun","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.jiph.2024.102583_bib9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1021\/acs.accounts.1c00697","article-title":"4'-modified nucleosides for antiviral drug discovery: achievements and perspectives","volume":"55","author":"Chang","year":"2022","journal-title":"Acc Chem Res"},{"issue":"6","key":"10.1016\/j.jiph.2024.102583_bib10","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug-drug interactions between the COVID-19 antiviral Nirmatrelvir\/Ritonavir (Paxlovid) and comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin Pharm Ther"},{"issue":"1","key":"10.1016\/j.jiph.2024.102583_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/cid\/ciac180","article-title":"Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs","volume":"76","author":"Saravolatz","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jiph.2024.102583_bib12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2204919","article-title":"Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge","volume":"387","author":"Arbel","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jiph.2024.102583_bib13","first-page":"638","article-title":"Molnupiravir and nirmatrelvir\/ritonavir: the new available antiviral options for COVID-19","volume":"54","author":"Sutanto","year":"2022","journal-title":"Acta Med Indones"},{"issue":"3","key":"10.1016\/j.jiph.2024.102583_bib14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.37201\/req\/002.2022","article-title":"Nirmatrelvir m\u00e1s ritonavir (Paxlovid) una potente combinaci\u00f3n inhibidora de la proteasa 3CLpro del SARS-CoV-2 [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination","volume":"35","author":"Reina","year":"2022","journal-title":"Rev Esp Quim"},{"issue":"4","key":"10.1016\/j.jiph.2024.102583_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28756","article-title":"Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study","volume":"95","author":"Deng","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.jiph.2024.102583_bib16","series-title":"Novel coronavirus (2019-nCoV): situation report, 1","author":"World Health, Organization","year":"2020"},{"issue":"3","key":"10.1016\/j.jiph.2024.102583_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/BSD.0000000000000932","article-title":"Propensity score matching: a statistical method","volume":"33","author":"Kane","year":"2020","journal-title":"Clin Spine Surg"},{"issue":"4","key":"10.1016\/j.jiph.2024.102583_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12998","article-title":"Coronavirus disease 2019 (COVID-19): an overview of the immunopathology, serological diagnosis and management","volume":"93","author":"Anka","year":"2021","journal-title":"Scand J Immunol"},{"issue":"5","key":"10.1016\/j.jiph.2024.102583_bib19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1053\/j.ackd.2020.09.001","article-title":"Treatment options for coronavirus disease 2019 in patients with reduced or absent kidney function","volume":"27","author":"Miller-Handley","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"10.1016\/j.jiph.2024.102583_bib20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1208\/s12249-020-01679-z","article-title":"Research progress of drug treatment in novel coronavirus pneumonia","volume":"21","author":"Yan","year":"2020","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.jiph.2024.102583_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijp.IJP_119_20","article-title":"Therapeutic options for the treatment of 2019-novel coronavirus: an evidence-based approach","volume":"52","author":"Sarma","year":"2020","journal-title":"Indian J Pharm"},{"issue":"4","key":"10.1016\/j.jiph.2024.102583_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.671","article-title":"Comparative evaluation of authorized drugs for treating Covid-19 patients","volume":"5","author":"Islam","year":"2022","journal-title":"Health Sci Rep"},{"issue":"3","key":"10.1016\/j.jiph.2024.102583_bib23","article-title":"Therapeutic strategies against COVID-19","volume":"91","author":"Esposito","year":"2020","journal-title":"Acta Biomed"},{"issue":"3","key":"10.1016\/j.jiph.2024.102583_bib24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.jiph.2024.102583_bib25","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.31557\/APJCP.2023.24.6.2157","article-title":"Safety assessment of a nucleoside analogue fnc (2'-deoxy-2'- \u03b2-fluoro-4'-azidocytidine) in balb\/c mice: acute toxicity study","volume":"24","author":"Kumar","year":"2023","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"10.1016\/j.jiph.2024.102583_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.jiph.2024.102583_bib27","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2023.28254","article-title":"Paxlovid is effective but underused-here's what the latest research says about rebound and more","volume":"331","author":"Rubin","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jiph.2024.102583_bib28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2208822","article-title":"VV116 versus nirmatrelvir-ritonavir for oral treatment of covid-19","volume":"388","author":"Cao","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jiph.2024.102583_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(23)00493-0","article-title":"PLATCOV collaborative group. antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial","volume":"24","author":"Schilling","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"15","key":"10.1016\/j.jiph.2024.102583_bib30","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jiph.2024.102583_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1765","article-title":"COVID-19 Rebound After VV116 vs nirmatrelvir-ritonavir treatment: a randomized clinical trial","volume":"7","author":"Yang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.jiph.2024.102583_bib32","first-page":"528","article-title":"[Extra-pulmonary clinical manifestations of novel coronavirus pneumonia]","volume":"28","author":"Li","year":"2020","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"6","key":"10.1016\/j.jiph.2024.102583_bib33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.jiph.2024.102583_bib34","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/ijlh.13273","article-title":"Manifestations of blood coagulation and its relation to clinical outcomes in severe COVID-19 patients: Retrospective analysis","volume":"42","author":"Zhang","year":"2020","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"10.1016\/j.jiph.2024.102583_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40477-020-00494-3","article-title":"2019 novel coronavirus (COVID-19) pneumonia complications: the importance of lung ultrasound","volume":"25","author":"Consoli","year":"2022","journal-title":"J Ultrasound"},{"issue":"4","key":"10.1016\/j.jiph.2024.102583_bib36","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.jiph.2024.102583_bib37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034124003174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034124003174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T11:29:39Z","timestamp":1732620579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034124003174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1876034124003174"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2024.102583","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2024.102583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"102583"}}